基于肿瘤临床前模型建立头颈癌新型药物基因组学的必要性及展望

doi:10.6040/j.issn.1671-7554.0.2021.0953

摘要/Abstract

摘要： 头颈癌是全球第七大恶性肿瘤类型,超过60%患者初次确诊即为中晚期。靶向治疗和免疫治疗的发展已经显著推动了头颈癌治疗策略的转型,但是临床获益有待进一步提升。肿瘤临床前模型保留了患者肿瘤的基因和表型的异质性,已广泛应用于临床前药物筛选和验证体系。药物基因组学通过将基因组学和药物响应进行匹配,能够基于肿瘤异质性基础进行患者分层,优化治疗策略并挖掘新治疗靶点。本文概述药物基因组学的发展史,从头颈癌治疗现状和异质性特征出发,探讨借助临床前模型开展新型药物基因组学的必要性和可行性。

关键词: 药物基因组学, 人源性肿瘤异种移植瘤, 人源肿瘤来源的原代肿瘤细胞, 肿瘤异质性, 头颈癌

Abstract: Head and neck cancer is the seventh common malignant tumor in the world. For more than 60% patients, the diagnosis is made at an intermediate or advanced stage. Although the development of targeted therapy and immunotherapy has significantly promoted the transformation of therapeutic strategies of head and neck cancer, there is still an urgent need to expand the clinical benefits. Preclinical models of cancer, which maintain the genetic and phenotypic heterogeneity from their parental tumors, have been widely used in the preclinical drug screening and validation. By matching genomics and drug response, pharmacogenomics can stratify patients based on tumor heterogeneity, optimize treatment strategies, and discover new therapeutic targets. This paper outlines the history of pharmacogenomics, and discusses the necessity and feasibility of developing pharmacogenomics with the aid of preclinical models in the context of the current treatment status and tumor heterogeneity of head and neck cancer.

Key words: Pharmacogenomics, Patient-derived xenografts, Patient-derived cancer cells, Tumor heterogeneity, Head and neck cancer

中图分类号:

R739.8

孙树洋,张志愿. 基于肿瘤临床前模型建立头颈癌新型药物基因组学的必要性及展望[J]. 山东大学学报 (医学版), 2021, 59(9): 57-63.

SUN Shuyang, ZHANG Zhiyuan. Establishing the novel pharmacogenomics of head and neck cancer based on preclinical tumor models: necessity and prospect[J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 57-63.

参考文献

[1] Turajlic S, Sottoriva A, Graham T, et al. Resolving genetic heterogeneity in cancer [J]. Nat Rev Genet, 2019, 20(7): 404-416.
[2] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021 [J]. Ca Cancer J Clin, 2021, 71(1): 7-33.
[3] Chow LQM. Head and neck cancer [J]. N Engl J Med, 2020, 382(1): 60-72.
[4] Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics [J]. Lancet, 2019, 394(10197): 521-532.
[5] Motulsky AG. Drug reactions enzymes, and biochemical genetics [J]. JAMA, 1957, 165(7): 835-837.
[6] Lehmann H, Ryan E. The familial incidence of low pseudocholinesterase level [J]. Lancet, 1956, 271(6934): 124.
[7] Kalow W, Staron N. On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers [J]. Can J Biochem Physiol, 1957, 35(12): 1305-1320.
[8] Alving AS, Carson PE, Flanagan CL, et al. Enzymatic deficiency in primaquine-sensitive erythrocytes [J]. Science, 1956, 124(3220): 484-485.
[9] Relling MV, Evans WE. Pharmacogenomics in the clinic [J]. Nature, 2015, 526(7573): 343-350.
[10] 黄民. 药物基因组学与合理用药 [J]. 药学进展, 2018, 42(4): 241-242. HUANG Min. Pharmacogenomics and rational drug use [J]. Progress in Pharmaceutical Sciences, 2018, 42(4): 241-242.
[11] Earl HM, Hiller L, Vallier A-L, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer(PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial [J]. Lancet, 2019, 393(10191): 2599-2612.
[12] Hehlmann R, Lauseker M, SauBele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants [J]. Leukemia, 2017, 31(11): 2398-2406.
[13] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [J]. N Engl J Med, 2010, 362(25): 2380-2388.
[14] Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer [J]. Nature, 2019, 575(7782): 299-309.
[15] Kim C, Gao R, Sei E, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing [J]. Cell, 2018, 173(4): 879-893.
[16] Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the rosetta stone of therapy resistance [J]. Cancer Cell, 2020, 37(4): 471-484.
[17] Hong SP, Chan TE, Lombardo Y, et al. Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy [J]. Nat Commun, 2019, 10(1): 3840.
[18] Shaffer SM, Dunagin MC, Torborg SR, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance [J]. Nature, 2017, 546(7658): 431-435.
[19] Murtuza A, Bulbul A, Shen JP, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer [J]. Cancer Res, 2019, 79(4): 689-698.
[20] Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer [J]. N Engl J Med, 2017, 376(7): 629-640.
[21] Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion [J]. Cancer Discov, 2018, 8(12): 1529-1539.
[22] Tanaka K, Yu HA, Yang S, et al. Targeting aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis [J]. Cancer Cell, 2021, S1535-6108(21)00383-4.
[23] D'Cruz AK, Vaish R, Kapre N, et al. Elective versus therapeutic neck dissection in node-negative oral cancer [J]. N Engl J Med, 2015, 373(6): 521-529.
[24] Santuray RT, Johnson DE, Grandis JR. New therapies in head and neck cancer [J]. Trends Cancer, 2018, 4(5): 385-396.
[25] Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy [J]. J Clin Oncol, 2007, 25(16): 2171-2177.
[26] Kim HS, Kwon HJ, Jung I, et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck [J]. Clin Cancer Res, 2015, 21(3): 544-552.
[27] William WN, Papadimitrakopoulou V, Lee JJ, et al. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer(EPOC)Randomized Clinical Trial [J]. JAMA Oncol, 2016, 2(2): 209-216.
[28] Hedberg ML, Peyser ND, Bauman JE, et al. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer [J]. J Exp Med, 2019, 216(2): 419-427.
[29] Adkins D, Ley J, Neupane P, et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial [J]. Lancet Oncol, 2019, 20(9): 1295-1305.
[30] Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048): a randomised, open-label, phase 3 study [J]. Lancet, 2019, 394(10212): 1915-1928.
[31] Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial [J]. Lancet Oncol, 2021, 22(6): 883-892.
[32] Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012): an open-label, multicentre, phase 1b trial [J]. Lancet Oncol, 2016, 17(7): 956-965.
[33] Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas [J]. Nature, 2015, 517(7536): 576-582.
[34] McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future [J]. Cell, 2017, 168(4): 613-628.
[35] Elkabets M, Pazarentzos E, Juric D, et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas [J]. Cancer Cell, 2015, 27(4): 533-546.
[36] Shu S, Wu HJ, Ge JY, et al. Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer [J]. Mol Cell, 2020, 78(6): 1096-1113.
[37] Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer [J]. Cancer Discov, 2020, 10(8): 1129-1139.
[38] Zhou R, Shi C, Tao W, et al. Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations [J]. Clin Cancer Res, 2019, 25(12): 3548-3560.
[39] Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response [J]. Nat Med, 2015, 21(11): 1318-1325.
[40] Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models: status quo, challenges and perspectives [J]. Nat Rev Cancer, 2017, 17(12): 751-765.
[41] Izumchenko E, Paz K, Ciznadija D, et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors [J]. Ann Oncol, 2017, 28(10): 2595-2605.
[42] Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity [J]. Nature, 2012, 483(7391): 603-607.
[43] Haibe-Kains B, El-Hachem N, Birkbak NJ, et al. Inconsistency in large pharmacogenomic studies [J]. Nature, 2013, 504(7480): 389-393.
[44] Cancer Cell Line Encyclopedia Consortium, Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets [J]. Nature, 2015, 528(7580): 84-87.
[45] Haverty PM, Lin E, Tan J, et al. Reproducible pharmacogenomic profiling of cancer cell line panels [J]. Nature, 2016, 533(7603): 333-337.
[46] Bruna A, Rueda OM, Greenwood W, et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds [J]. Cell, 2016, 167(1): 260-274..
[47] Qiu Z, Li H, Zhang Z, et al. A pharmacogenomic landscape in human liver cancers [J]. Cancer Cell, 2019, 36(2):179-193.
[48] Sa JK, Hwang JR, Cho Y-J, et al. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers [J]. Genome Biol, 2019, 20(1): 253.
[49] Sa JK, Hong JY, Lee I-K, et al. Comprehensive pharmacogenomic characterization of gastric cancer [J]. Genome Med, 2020, 12(1): 17.
[50] Byrne AT, Alferez DG, Amant F, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts [J]. Nat Rev Cancer, 2017, 17(4): 254-268.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed